GRI Bio (NASDAQ:GRI – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.74) by $2.13, FiscalAI reports.
GRI Bio Trading Down 5.0%
NASDAQ GRI traded down $0.11 during trading on Friday, hitting $2.04. 19,177 shares of the company traded hands, compared to its average volume of 277,024. GRI Bio has a 12 month low of $2.03 and a 12 month high of $80.36. The business has a fifty day simple moving average of $2.43 and a 200 day simple moving average of $15.04. The company has a market capitalization of $2.95 million, a P/E ratio of -0.01 and a beta of -1.22.
Analysts Set New Price Targets
Several brokerages have weighed in on GRI. Wall Street Zen lowered GRI Bio to a “strong sell” rating in a research report on Saturday, January 31st. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $1,008.00.
GRI Bio Company Profile
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Read More
- Five stocks we like better than GRI Bio
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
